WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 2 fonti

Regenxbio presents long-term data for surabgene lomparvovec

Regenxbio (RGNX) announced positive data from long-term follow-up studies of investigational surabgene lomparvovec in wet AMD using subretinal d...

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

tipranks.comStai leggendo2 g fa

Regenxbio presents long-term data for surabgene lomparvovec

Regenxbio (RGNX) announced positive data from long-term follow-up studies of investigational surabgene lomparvovec in wet AMD using subretinal d...

benzinga.com1 g fa

Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments - Regenxbio (NASDAQ:RGNX)

REGENXBIO announced positive long-term sura-vec trial data for wet AMD and diabetic retinopathy, alongside a $100 million offering.

Leggi questa versione → originale

Timeline cronologica

domenica 19 luglio 2026·tipranks.com
Regenxbio presents long-term data for surabgene lomparvovec
Regenxbio (RGNX) announced positive data from long-term follow-up studies of investigational surabgene lomparvovec in wet AMD using subretinal d...
lunedì 20 luglio 2026·benzinga.com
Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments - Regenxbio (NASDAQ:RGNX)
REGENXBIO announced positive long-term sura-vec trial data for wet AMD and diabetic retinopathy, alongside a $100 million offering.